clb-10q_2q2010.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
     
FORM 10-Q
 
(Mark One)
 
   
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2010
 
OR
 
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from ________________ to ______________
 
Commission File Number:  001-14273
 
CORE LABORATORIES N.V.
(Exact name of registrant as specified in its charter)
 
The Netherlands
Not Applicable
(State of other jurisdiction of
(I.R.S. Employer Identification No.)
incorporation or organization)
 
   
Herengracht 424
 
1017 BZ Amsterdam
 
The Netherlands
Not Applicable
(Address of principal executive offices)
(Zip Code)
   
(31-20) 420-3191
(Registrant's telephone number, including area code)
 
None
(Former name, former address and former fiscal year, if changed since last report)

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes ý  No ¨

    Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes ý  No ¨

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ý
Accelerated filer  ¨
Non-accelerated filer  ¨
Smaller reporting company  ¨
   
(Do not check if a smaller reporting company)

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨  No ý

    The number of common shares of the registrant, par value EUR 0.02 per share, outstanding at July 22, 2010 was 44,675,908.


 
 

 


CORE LABORATORIES N.V.
FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2010
 
 
 
Page
PART I - FINANCIAL INFORMATION
 
Item 1.
Financial Statements
 
     
 
1
     
 
2
     
 
3
     
 
4
     
 
5
     
Item 2.
17
     
Item 3.
25
     
Item 4.
25
     
     
PART II - OTHER INFORMATION
     
Item 1.
26
     
Item 2.
26
     
Item 6.
27
     
 
28
     

 
 

 

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

CORE LABORATORIES N.V.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)

   
June 30,
   
December 31,
 
   
2010
   
2009
 
ASSETS
 
(Unaudited)
       
CURRENT ASSETS:
           
Cash and cash equivalents
  $ 173,622     $ 181,045  
Accounts receivable, net of allowance for doubtful accounts of $3,571 and  
$3,202 at 2010 and 2009, respectively
    137,565       133,758  
Inventories, net
    33,762       32,184  
Prepaid expenses and other current assets
    29,022       43,550  
TOTAL CURRENT ASSETS
    373,971       390,537  
                 
PROPERTY, PLANT AND EQUIPMENT, net
    100,680       98,784  
INTANGIBLES, net
    9,191       6,520  
GOODWILL
    154,217       148,600  
OTHER ASSETS
    14,602       13,725  
TOTAL ASSETS
  $ 652,661     $ 658,166  
                 
LIABILITIES AND EQUITY
               
CURRENT LIABILITIES:
               
Accounts payable
  $ 39,528     $ 33,009  
Accrued payroll and related costs
    23,140       24,368  
Taxes other than payroll and income
    6,817       8,183  
Unearned revenues
    18,472       16,528  
Income tax payable
    23,001       15,433  
Short-term debt – Senior Exchangeable Notes
    216,787       -  
Other accrued expenses
    9,667       8,887  
TOTAL CURRENT LIABILITIES
    337,412       106,408  
                 
LONG-TERM DEBT – SENIOR EXCHANGEABLE NOTES
    -       209,112  
DEFERRED COMPENSATION
    18,143       16,866  
DEFERRED TAX LIABILITIES
    8,239       7,692  
OTHER LONG-TERM LIABILITIES
    32,603       36,330  
COMMITMENTS AND CONTINGENCIES
    -       -  
                 
EQUITY COMPONENT OF SHORT-TERM DEBT – SENIOR EXCHANGEABLE NOTES
    21,871       -  
                 
EQUITY:
               
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized,
none issued or outstanding
    -       -  
Common shares, EUR 0.02 par value;
200,000,000 shares authorized, 51,039,912 issued and 44,675,908 outstanding at 2010 and
51,039,912 issued and 45,973,408 outstanding at 2009
    1,430       1,430  
Additional paid-in capital
    37,149       61,719  
Retained earnings
    530,500       469,454  
Accumulated other comprehensive (loss)
    (6,365 )     (6,536 )
Treasury shares (at cost), 6,364,004 at 2010 and 5,066,504 at 2009
    (330,757 )     (246,699 )
      Total Core Laboratories N.V. shareholders' equity
    231,957       279,368  
Non-controlling interest
    2,436       2,390  
TOTAL EQUITY
    234,393       281,758  
TOTAL LIABILITIES AND EQUITY
  $ 652,661     $ 658,166  


The accompanying notes are an integral part of these consolidated financial statements.

1

 

CORE LABORATORIES N.V.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)

   
Three Months Ended
June 30,
 
 
 
2010
   
2009
 
   
(Unaudited)
 
REVENUES:
           
Services
  $ 153,010     $ 134,671  
Product sales
    45,892       32,591  
      198,902       167,262  
OPERATING EXPENSES:
               
Cost of services, exclusive of depreciation expense shown below
    96,411       84,401  
Cost of product sales, exclusive of depreciation expense shown below
    32,506       24,596  
General and administrative expenses
    9,211       6,684  
Depreciation
    5,430       5,724  
Amortization
    336       182  
Other expense (income), net
    1,288       (6,013 )
OPERATING INCOME
    53,720       51,688  
Interest expense
    4,114       3,840  
Income before income tax expense
    49,606       47,848  
Income tax expense
    15,244       17,884  
Net income
    34,362       29,964  
    Net income attributable to non-controlling interest
    146       157  
Net income attributable to Core Laboratories N.V.
  $ 34,216     $ 29,807  
                 
EARNINGS PER SHARE INFORMATION:
               
Basic earnings per share attributable to Core Laboratories N.V.
  $    0.77     $    0.65  
                 
Diluted earnings per share attributable to Core Laboratories N.V.
  $ 0.71     $ 0.64  
                 
Cash dividends per share
  $ 0.06     $ 0.05  
                 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
               
Basic
    44,651       45,911  
                 
Diluted
    47,957       46,357  
                 

















The accompanying notes are an integral part of these consolidated financial statements.

2

 

CORE LABORATORIES N.V.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)

   
Six Months Ended
June 30,
 
 
 
2010
   
2009
 
   
(Unaudited)
 
REVENUES:
           
Services
  $ 296,452     $ 276,363  
Product sales
    90,787       69,775  
      387,239       346,138  
OPERATING EXPENSES:
               
Cost of services, exclusive of depreciation expense shown below
    191,768       172,697  
Cost of product sales, exclusive of depreciation expense shown below
    62,737       52,332  
General and administrative expenses
    15,591       15,958  
Depreciation
    10,849       11,251  
Amortization
    671       363  
Other expense (income), net
    490       (4,770 )
OPERATING INCOME
    105,133       98,307  
Interest expense
    8,173       7,640  
Income before income tax expense
    96,960       90,667  
Income tax expense
    30,312       31,464  
Net income
    66,648       59,203  
    Net income attributable to non-controlling interest
    227       204  
Net income attributable to Core Laboratories N.V.
  $ 66,421     $ 58,999  
                 
EARNINGS PER SHARE INFORMATION:
               
Basic earnings per share attributable to Core Laboratories N.V.
  $    1.48     $    1.28  
                 
Diluted earnings per share attributable to Core Laboratories N.V.
  $ 1.40     $ 1.27  
                 
Cash dividends per share
  $ 0.12     $ 0.10  
                 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
               
Basic
    44,743       45,925  
                 
Diluted
    47,396       46,383  
                 


















The accompanying notes are an integral part of these consolidated financial statements.

3

 


CORE LABORATORIES N.V.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

   
Six Months Ended
June 30,
 
 
 
2010
   
2009
 
   
(Unaudited)
 
CASH FLOWS FROM OPERATING ACTIVITIES:
           
Net income
  $ 66,648     $ 59,203  
Adjustments to reconcile net income to net cash provided by operating activities:
               
Net provision for (recoveries of) doubtful accounts
    811       319  
Provisions for inventory obsolescence
    298       103  
Equity in earnings of affiliates
    (239 )     (78 )
Stock-based compensation
    3,836       2,624  
Depreciation and amortization
    11,520       11,614  
Non-cash interest expense
    7,735       7,213  
Gain on sale of assets
    8       (345 )
Realization of pension obligation
    171       117  
(Increase) decrease in value of life insurance policies
    765       (421 )
Deferred income taxes
    (8,822 )     (8,145 )
Changes in assets and liabilities:
               
Accounts receivable
    (4,618 )     20,028  
Inventories
    (1,876 )     (2,123 )
Prepaid expenses and other current assets
    23,896       724  
Other assets
    (540 )     (252 )
Accounts payable
    6,519       (14,748 )
Accrued expenses
    7,698       1,948  
Other long-term liabilities
    (2,450 )     8,486  
Net cash provided by operating activities
    111,360       86,267  
CASH FLOWS FROM INVESTING ACTIVITIES:
               
Capital expenditures
    (12,696 )     (5,320 )
Patents and other intangibles
    (142 )     (151 )
Acquisitions
    (9,000 )     -  
Proceeds from sale of assets
    125       459  
Premiums on life insurance
    (921 )     (844 )
Net cash used in investing activities
    (22,634 )     (5,856 )
CASH FLOWS FROM FINANCING ACTIVITIES:
               
Stock options exercised
    295       302  
Excess tax benefits from stock-based compensation
    798       127  
Non-controlling interest - dividends
    (181 )     (246 )
Dividends paid
    (5,375 )     (4,597 )
Repurchase of common shares
    (91,686 )     (8,889 )
Net cash used in financing activities
    (96,149 )     (13,303 )
NET CHANGE IN CASH AND CASH EQUIVALENTS
    (7,423 )     67,108  
CASH AND CASH EQUIVALENTS, beginning of period
    181,045       36,138  
CASH AND CASH EQUIVALENTS, end of period
  $ 173,622     $  103,246  
                 
Non-cash investing and financing activities:
               
Financed capital expenditures
  $ -     $ 2,871  
                 





The accompanying notes are an integral part of these consolidated financial statements.

4

 

CORE LABORATORIES N.V.
NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1.  BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements include the accounts of Core Laboratories N.V. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP") for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP and should be read in conjunction with the financial statements and the summary of significant accounting policies and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2009.

Core Laboratories N.V. uses the equity method of accounting for investments in which it has less than a majority interest and over which it does not exercise control. Non-controlling interest has been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned.  In the opinion of management, all adjustments considered necessary for the periods presented have been included in these financial statements.  Furthermore, the operating results presented for the three and six months ended June 30, 2010 may not necessarily be indicative of the results that may be expected for the year ended December 31, 2010.

Core Laboratories N.V.'s balance sheet information for the year ended December 31, 2009 was derived from the 2009 audited consolidated financial statements but does not include all disclosures in accordance with U.S. GAAP.

At our annual meeting on June 10, 2010, the shareholders approved an amendment to increase the authorized shares of our common stock from 100 million to 200 million and to increase the authorized shares of our preference stock from 3 million to 6 million.  In addition, shareholders approved the two-for-one stock split authorized by the Supervisory Board and thereby reduced the par value of each share from EUR 0.04 to EUR 0.02. As a result of the stock split, shareholders of record on June 30, 2010 received an additional share of common stock for each common share held.  The additional shares were distributed on July 8, 2010.  All references in the consolidated financial statements and the accompanying notes to common shares, share prices, per share amounts and stock plans have been restated retroactively for the stock split.

Certain reclassifications were made to prior period amounts in order to conform to the current period presentation.  These reclassifications had no impact on the reported net income for the three month and six month periods ended June 30, 2010.

References to "Core Lab", "we", "our" and similar phrases are used throughout this Quarterly Report on Form 10-Q and relate collectively to Core Laboratories N.V. and its consolidated subsidiaries.


2.  INVENTORIES

Inventories consist of the following (in thousands):

   
June 30,
   
December 31,
 
   
2010
   
2009
 
   
(Unaudited)
       
Finished goods
  $ 22,503     $ 22,161  
Parts and materials
    8,823       8,756  
Work in progress
    2,436       1,267  
  Total inventories, net
  $ 33,762     $ 32,184  

We include freight costs incurred for shipping inventory to customers in the Cost of Sales line of the Consolidated Statements of Operations.


3. GOODWILL AND INTANGIBLES

We account for intangible assets with indefinite lives, including goodwill, in accordance with the applicable accounting guidance, which requires us to evaluate these assets for impairment annually, or more frequently if an indication of impairment has occurred.  Based upon our most recent evaluation, we did not identify a triggering event; therefore, we have determined that goodwill is not impaired.  We amortize intangible assets with a defined term on a straight-line basis over their respective useful lives.

5

 


In January 2010, we acquired fracture diagnostics assets for $9.0 million in cash.  The acquisition was recorded in the Production Enhancement business segment and resulted in an increase of $5.6 million in goodwill and an increase of $3.2 million in intangible assets.  The intangible assets will be amortized over a period of 36 to 60 months.  The acquisition did not have a material impact to the Production Enhancement business segment or consolidated operating results for the six months ended June 30, 2010.  The remaining composition of goodwill by business segment at June 30, 2010 was consistent with the amounts disclosed in our Annual Report on Form 10-K as of December 31, 2009.


4.  DEBT AND CAPITAL LEASE OBLIGATIONS

Debt is summarized in the following table (in thousands):

   
June 30,
   
December 31,
 
   
2010
   
2009
 
   
(Unaudited)
       
Senior exchangeable notes
  $ 238,658     $ 238,658  
Discount on senior exchangeable notes
    (21,871 )     (29,546 )
  Net senior exchangeable notes
  $ 216,787     $ 209,112  

In 2006, Core Laboratories LP, a wholly owned subsidiary of Core Laboratories N.V., issued $300 million aggregate principal amount of Senior Exchangeable Notes (the "Notes") which are fully and unconditionally guaranteed by Core Laboratories N.V. and mature on October 31, 2011.  The Notes bear interest at a rate of 0.25% per year paid on a semi-annual basis.

With the additional amortization of the discount on the Notes, the effective interest rate is 7.48% for the six-month period ended June 30, 2010, which resulted in additional non-cash interest expense of $3.9 million and $3.6 million for the three months ended June 30, 2010 and 2009, respectively, and $7.7 million and $7.1 million for the six months ended June 30, 2010 and 2009, respectively.  Each Note carries a $1,000 principal amount and is exchangeable into shares of Core Laboratories N.V. under certain circumstances at an exchange price of $46.21 per share, or 21.6434 shares per Note.  Upon exchange, holders will receive cash for the principal amount plus any amount related to fractional shares, and any excess exchange value will be delivered in whole shares of Core Laboratories N.V. common shares.  The carrying value of the equity component of the Notes is $84.4 million at June 30, 2010 and December 31, 2009. At June 30, 2010, the Notes were trading at 162.0% of their face value which would result in $148.0 million of value in excess of the principal. At December 31, 2009, the Notes were trading at 134% of their face value which would result in $81.1 million of value in excess of the principal.  There were 238,658 Notes outstanding at June 30, 2010.

Under the terms of the Notes, in the second quarter of 2010, the early exchange option for the holders of the Notes was enabled. As a result, the Notes can be exchanged during the third quarter of 2010 and will remain classified as a short-term liability at June 30, 2010.  In addition, the equity component of the Notes was classified as temporary equity to reflect the amount that could result in cash settlement at June 30, 2010.  In the first quarter of 2010, the early exchange option was enabled allowing the holders of the Notes to exchange them during the second quarter of 2010.  We received six requests during the second quarter of 2010 to exchange 28 Notes, which we will settle during the third quarter.

We maintain a revolving credit facility (the "Credit Facility") that allows for an aggregate borrowing capacity of $100.0 million. The Credit Facility provides an option to increase the commitment under the Credit Facility to $150.0 million, if certain conditions are met.  The Credit Facility bears interest at variable rates from LIBOR plus 0.5% to a maximum of LIBOR plus 1.125%.  Any outstanding balance under the Credit Facility is due in December 2010 when the Credit Facility matures.  Interest payment terms are variable depending upon the specific type of borrowing under this facility. Our available borrowing capacity under the Credit Facility was reduced by outstanding letters of credit and performance guarantees and bonds arranged totaling $12.6 million at June 30, 2010 relating to certain projects in progress.  Our available borrowing capacity under the Credit Facility at June 30, 2010 was $87.4 million. As of June 30, 2010, we had $14.9 million of outstanding letters of credit and performance guarantees and bonds in addition to those under the Credit Facility.


5.  PENSIONS AND OTHER POSTRETIREMENT BENEFITS

We provide a noncontributory defined benefit pension plan covering substantially all of our Dutch employees (the "Dutch Plan") who were hired prior to 2007 based on years of service and final pay or career average pay, depending on when the employee began participating. Employees are immediately vested in the benefits earned.  We fund the future obligations of the Dutch Plan by purchasing investment contracts from a large multi-national insurance company.  The investment contracts are

6

 

purchased annually and expire after five years at which time they are replaced with new contracts that are adjusted to include changes in the benefit obligation for the current year and redemption of the expired contracts.  We determine the fair value of
these plan assets with the assistance of an actuary using observable inputs (Level 2).  We make annual premium payments to the insurance company, based on each employee's age and current salary.

The following table summarizes the components of net periodic pension cost under this plan for the three and six months ended June 30, 2010 and 2009 (in thousands):


   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2010
   
2009
   
2010
   
2009
 
   
(Unaudited)
   
(Unaudited)
 
Service cost
  $ 304     $ 265     $ 627     $ 518  
Interest cost
    352       339       728       663  
Expected return on plan assets
    (111 )     (186 )     (230 )     (364 )
Amortization of transition asset
    (22 )     (22 )     (44 )     (44 )
Amortization of prior service cost
    40       40       80       80  
Amortization of net loss
    95       61       189       122  
   Net periodic pension cost
  $ 658     $ 497     $ 1,350     $ 975  

During the six months ended June 30, 2010, we contributed approximately $1.1 million, as determined by the insurance company, to fund the estimated 2010 premiums on investment contracts held by the plan.

We have adopted a non-qualified deferred compensation plan that allows certain highly compensated employees to defer a portion of their salary, commission and bonus, as well as the amount of any reductions in their deferrals under the deferred compensation plan for employees in the United States (the "Deferred Compensation Plan"), due to certain limitations imposed by the U.S. Internal Revenue Code of 1986, as amended (the "Internal Revenue Code").  The Deferred Compensation Plan also provides for employer contributions to be made on behalf of participants equal in amount to certain forfeitures of, and/or reductions in, employer contributions that participants could have received under the 401(k) Plan in the absence of certain limitations imposed by the Internal Revenue Code. Employer contributions to the Deferred Compensation Plan vest ratably over a period of five years. Contributions to the plan are invested in equity and other investment fund assets, and carried on the balance sheet at fair value.  The benefits under these contracts are fully vested and payment of benefits generally commences as of the last day of the month following the termination of services except that the payment of benefits for select executives generally commences on the first working day following a six month waiting period following the date of termination.

On a recurring basis, we use the market approach to value certain assets and liabilities at fair value at quoted prices in an active market (Level 1) and certain assets and liabilities using significant other observable inputs (Level 2). We do not have any assets or liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3). Gains and losses related to the fair value changes in the deferred compensation assets and liabilities are recorded in General and Administrative Expenses in the Consolidated Statements of Operations.  The following table summarizes the fair value balances (in thousands):

(Unaudited)
       
Fair Value Measurement at June 30, 2010
 
   
Total
   
Level 1
   
Level 2
   
Level 3
 
Assets:
                       
   Deferred compensation plan trust assets
  $ 6,266     $ -     $ 6,266     $ -  
                                 
Liabilities:
                               
   Deferred compensation plan
  $ 9,894     $ 1,767     $ 8,127     $ -  

         
Fair Value Measurement at December 31, 2009
 
   
Total
   
Level 1
   
Level 2
   
Level 3
 
Assets:
                       
   Deferred compensation plan trust assets
  $ 6,193     $ -     $ 6,193     $ -  
                                 
Liabilities:
                               
   Deferred compensation plan
  $ 9,366     $ 1,339     $ 8,027     $ -  


7

 


6. COMMITMENTS AND CONTINGENCIES

From time to time, we may be subject to legal proceedings and claims that arise in the ordinary course of business.  We believe that the resolution of all litigation currently pending or threatened against us or any of our subsidiaries should not have a material adverse effect on our consolidated financial condition, results of operations or liquidity; however, because of the inherent uncertainty of litigation, we cannot provide assurance that the resolution of any particular claim or proceeding to which we or any of our subsidiaries is a party will not have a material adverse effect on our consolidated results of operations or liquidity for the period in which that resolution occurs.


7.  EQUITY

During the three months ended June 30, 2010, we repurchased 75,476 of our common shares for $5.2 million. Included in this total were rights to 35,476 shares valued at $2.5 million that were surrendered to us pursuant to the terms of a stock-based compensation plan, in consideration of the participants' tax burdens that may result from the issuance of common shares under this plan.  During the six months ended June 30, 2010, we repurchased 1,483,280 of our common shares for $91.7 million. Included in this total were rights to 42,534 shares valued at $2.9 million that were surrendered to us pursuant to the terms of a stock-based compensation plan, in consideration of the participants' tax burdens that may result from the issuance of common shares under this plan. Such common shares, unless cancelled, may be reissued for a variety of purposes such as future acquisitions, employee stock awards, possible exchange of the Notes or settlement of warrants.

During the three and six months ended June 30, 2010, we recognized tax benefits of $0.9 million and $0.8 million, respectively, relating to tax deductions in excess of book expense for stock-based compensation awards.  These tax benefits are recorded to additional paid-in capital to the extent deductions reduce current taxable income.

At the annual meeting of shareholders on June 10, 2010, the shareholders approved the cancellation of 1.3 million shares of our common stock currently held as treasury stock.  These treasury shares will be cancelled on or about August 14, 2010, after the expiration of the waiting period required under Dutch law.

In February and May 2010, we paid a quarterly dividend of $0.06 per share of common stock.  In addition, on July 12, 2010, we declared a quarterly dividend of $0.06 per share of common stock and a special non-recurring cash dividend of $0.65 per share of common stock for shareholders of record on July 23, 2010 and payable on August 23, 2010.

The following table summarizes our changes in equity for the six months ended June 30, 2010 (in thousands):

                     
Accumulated
                   
         
Additional
         
Other
         
Non-
       
   
Common
   
Paid-In
   
Retained
   
Comprehensive
   
Treasury
   
Controlling
   
Total
 
(Unaudited)
 
Shares
   
Capital
   
Earnings
   
Income (Loss)
   
Stock
   
Interest
   
Equity
 
                                           
December 31, 2009
  $ 1,430     $ 61,719     $ 469,454     $ (6,536 )   $ (246,699 )   $ 2,390     $ 281,758  
Stock options exercised
    -       (1,353 )     -       -       1,648       -       295  
Stock based-awards
    -       (2,144 )     -       -       5,980       -       3,836  
Tax benefit of stock-based awards issued
    -       798       -       -       -       -       798  
Repurchase of common shares
    -       -       -       -       (91,686 )     -       (91,686 )
Dividends paid
    -       -       (5,375 )     -       -       -       (5,375 )
Equity component of short-term debt
    -       (21,871 )     -       -       -       -       (21,871 )
Non-controlling interest dividend
    -       -       -       -       -       (181 )     (181 )
Comprehensive income:
                                                       
Amortization of pension,
net of tax
    -       -       -       171       -       -       171  
Net income
    -       -       66,421       -       -       227       66,648  
Total comprehensive income
                                                    66,819  
                                                         
June 30, 2010
  $ 1,430     $ 37,149     $ 530,500     $ (6,365 )   $ (330,757 )   $ 2,436     $ 234,393  

Comprehensive Income

8

 


The components of comprehensive income consisted of the following (in thousands):

   
Three months ended June 30,
   
Six months ended June 30,
 
   
2010
   
2009
   
2010
   
2009
 
   
(Unaudited)
   
(Unaudited)
 
Net income
  $ 34,362     $ 29,964     $ 66,648     $ 59,203  
Realization of pension obligation
    86       59       171       117  
  Total comprehensive income
  $ 34,448     $ 30,023     $ 66,819     $ 59,320  

Accumulated other comprehensive income (loss) consisted of the following (in thousands):

   
June 30,
   
December 31,
 
   
2010
   
2009
 
   
(Unaudited)
       
Prior service cost
  $ (911 )   $ (971 )
Transition asset
    356       389  
Unrecognized net actuarial loss
    (5,810 )     (5,954 )
  Total accumulated other comprehensive loss
  $ (6,365 )   $ (6,536 )


8.  EARNINGS PER SHARE

We compute basic earnings per common share by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common and potential common shares include additional shares in the weighted average share calculations associated with the incremental effect of dilutive employee stock options, restricted stock awards and contingently issuable shares, as determined using the treasury stock method. The following table summarizes the calculation of weighted average common shares outstanding used in the computation of diluted earnings per share (in thousands):

   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2010
   
2009
   
2010
   
2009
 
   
(Unaudited)
   
(Unaudited)
 
Weighted average basic common shares outstanding
    44,651       45,911       44,743       45,925  
Effect of dilutive securities:
                               
Stock options
    55       96       56       142  
Contingent shares
    44       32       37       30  
Restricted stock and other
    568       318       550       286  
Senior exchangeable notes
    1,823       -       1,586       -  
Warrants
    816       -       424       -  
Weighted average diluted common and potential common shares outstanding
    47,957       46,357       47,396       46,383  

In 2006, we sold warrants on our common shares, which currently have an exercise price of $62.21 per share, and will settle in January 2012.  The net value of these warrants will be settled with Core Laboratories N.V. common shares.  Included in the table above are 816,000 and 424,000 shares which were added to the share count for the three and six months ended June 30, 2010 because the average share price exceeded the strike price of the warrants.  These shares were included in calculating the impact to our dilutive earnings per share for the three and six months ended June 30, 2010.


9

 


9. OTHER EXPENSE (INCOME), NET

The components of other expense (income), net, were as follows (in thousands):

   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2010
   
2009
   
2010
   
2009
 
   
(Unaudited)
   
(Unaudited)
 
Gain on sale of assets
  $ 39     $ (268 )   $ 8     $ (345 )
Foreign exchange loss (gain)
    1,712       (2,897 )     1,621       (1,009 )
Interest income
    (130 )     (59 )     (142 )     (98 )
Non-income tax accrual
    -       (2,500 )     -       (2,500 )
Rents and royalties
    (218 )     (508 )     (700 )     (849 )
Other, net
    (115 )     219       (297 )     31  
  Total other expense (income), net
  $ 1,288     $ (6,013 )   $ 490     $ (4,770 )

As a result of finalizing a non-income related tax settlement agreement, we released the remaining $2.5 million of the contingent liability during the second quarter of 2009.


Foreign exchange losses (gains) by currency are summarized in the following table (in thousands):

   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2010
   
2009
   
2010
   
2009
 
   
(Unaudited)
   
(Unaudited)
 
Australian Dollar
  $ 103     $ (300 )   $ 103     $ (278 )
British Pound
    158       (304 )     416       (232 )
Canadian Dollar
    149       (1,115 )     (236 )     (767 )
Euro
    1,619       (376 )     1,589       (213 )
Russian Ruble
    (69 )     (372 )     (15 )     224  
Venezuelan Bolivar
    (202 )     (1 )     (191 )     (1 )
Other currencies, net
    (46 )     (429 )     (45 )     258  
  Total loss (gain)
  $ 1,712     $ (2,897 )   $ 1,621     $ (1,009 )


10.  INCOME TAX EXPENSE

The effective tax rates for the three months ended June 30, 2010 and 2009 were 30.7% and 37.4%, respectively.  The effective tax rates for year to date 2010 and 2009 were 31.3% and 34.7%, respectively. The higher effective tax rate for 2009 was primarily due to a write down of assets in Venezuela without a tax benefit in the second quarter last year.

11.  SEGMENT REPORTING

We operate our business in three reportable segments:  (1) Reservoir Description, (2) Production Enhancement and (3) Reservoir Management.  These business segments provide different services and utilize different technologies.

*
Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.
   
*
Production Enhancement: Includes products and services relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
   
*
Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.


10

 


Results for these business segments are presented below.  We use the same accounting policies to prepare our business segment results as are used to prepare our Consolidated Financial Statements.  We evaluate performance based on income or loss before income tax, interest and other non-operating income (expense). Summarized financial information concerning our segments is shown in the following table (in thousands):
 

(Unaudited)
 
Reservoir Description
   
Production Enhancement
   
Reservoir Management
   
Corporate & Other 1
   
Consolidated
 
Three Months Ended June 30, 2010
                             
Revenues from unaffiliated customers
  $ 106,528     $ 79,717     $ 12,657     $ -     $ 198,902  
Inter-segment revenues
    248       419       427       (1,094 )     -  
Segment operating income
    25,074       26,152       3,672       (1,178 )     53,720  
Total assets
    258,759       190,512       14,245       189,145       652,661  
Capital expenditures
    4,600       720       219       1,002       6,541  
Depreciation and amortization
    3,523       1,626       166       451       5,766  
                                         
Three Months Ended June 30, 2009
                                       
Revenues from unaffiliated customers
  $ 103,479     $ 52,014     $ 11,769     $ -     $ 167,262  
Inter-segment revenues
    351       447       355       (1,153 )     -  
Segment operating income (loss)
    31,462       14,419       3,484       2,323       51,688  
Total assets
    255,448       172,095       17,929       130,402       575,874  
Capital expenditures
    2,120       401       52       92       2,665  
Depreciation and amortization
    3,593       1,462       178       673       5,906  
                                         
Six Months Ended June 30, 2010
                                       
Revenues from unaffiliated customers
  $ 210,621     $ 148,561     $ 28,057     $ -     $ 387,239  
Inter-segment revenues
    548       713       715       (1,976 )     -  
Segment operating income
    50,215       47,095       9,292       (1,469 )     105,133  
Total assets
    258,759       190,512       14,245       189,145       652,661  
Capital expenditures
    9,929       1,392       257       1,118       12,696  
Depreciation and amortization
    7,030       3,249       324       917       11,520  
                                         
Six Months Ended June 30, 2009
                                       
Revenues from unaffiliated customers
  $ 206,002     $ 115,114     $ 25,022     $ -     $ 346,138  
Inter-segment revenues
    474       808       736       (2,018 )     -  
Segment operating income (loss)
    56,214       32,743       6,962       2,388       98,307  
Total assets
    255,448       172,095       17,929       130,402       575,874  
Capital expenditures
    4,183       988       52       97       5,320  
Depreciation and amortization
    6,950       2,924       355       1,385       11,614  
                                         
(1) "Corporate & Other" represents those items that are not directly related to a particular segment and eliminations.
 


12. CONDENSED CONSOLIDATING FINANCIAL INFORMATION

Core Laboratories N.V. has fully and unconditionally guaranteed all of the Notes issued by Core Laboratories LP in 2006. Core Laboratories LP is a wholly owned subsidiary of Core Laboratories N.V.

The following condensed consolidating financial information is included so that separate financial statements of Core Laboratories LP are not required to be filed with the U.S. Securities and Exchange Commission (the "SEC"). The condensed consolidating financial statements present investments in both consolidated and unconsolidated affiliates using the equity method of accounting.

The following condensed consolidating financial information presents: balance sheets as of June 30, 2010 and December 31, 2009, statements of operations for each of the three and six months ended June 30, 2010 and 2009 and the statements of cash flows for each of the six months ended June 30, 2010 and 2009 of (a) Core Laboratories N.V., parent/guarantor, (b) Core Laboratories LP, issuer of public debt securities guaranteed by Core Laboratories N.V., (c) the non-guarantor subsidiaries, (d) consolidating adjustments necessary to consolidate Core Laboratories N.V. and its subsidiaries and (e) Core Laboratories N.V. on a consolidated basis.




11

 


Condensed Consolidating Balance Sheets (Unaudited)
                         
                               
(In thousands)
 
June 30, 2010
 
   
Core Laboratories N.V. (Parent/ Guarantor)
   
Core Laboratories LP (Issuer)
   
Other Subsidiaries (Non- Guarantors)
   
Consolidating Adjustments
   
Consolidated Total
 
ASSETS
                             
CURRENT ASSETS:
                             
Cash and cash equivalents
  $ 32,379     $ 127,184     $ 14,059     $ -     $ 173,622  
Accounts receivable, net
    1       30,072       107,492       -       137,565  
Inventories, net
    -       3,584       30,178       -       33,762  
Prepaid expenses and other current assets
    7,097       11,221       10,704       -       29,022  
Total current assets
    39,477       172,061       162,433       -       373,971  
                                         
PROPERTY, PLANT AND EQUIPMENT, net
    -       21,822       78,858       -       100,680  
GOODWILL AND INTANGIBLES, net
    46,986       16,275       100,147       -       163,408  
INTERCOMPANY RECEIVABLES
    -       261,797       329,159       (590,956 )     -  
INVESTMENT IN AFFILIATES
    609,764       -       1,731,110       (2,340,315 )     559  
DEFERRED TAX ASSET
    2,610       -       6,671       (9,281 )     -  
OTHER ASSETS
    2,670       8,835       2,538       -       14,043  
TOTAL ASSETS
  $ 701,507     $ 480,790     $ 2,410,916     $ (2,940,552 )   $ 652,661  
                                         
LIABILITIES AND EQUITY
                                 
CURRENT LIABILITIES:
                                       
Accounts payable
  $ 193     $ 7,177     $ 32,158     $ -     $ 39,528  
Short-term debt
     -       216,787       -       -       216,787  
Other accrued expenses
    2,111       26,534       52,452       -       81,097  
Total current liabilities
    2,304       250,498       84,610       -       337,412  
                                         
LONG-TERM DEBT
    -       -       -       -       -  
DEFERRED COMPENSATION
    6,352       11,695       96       -       18,143  
DEFERRED TAX LIABILITY
    -       17,520       -       (9,281 )     8,239  
INTERCOMPANY PAYABLES
    447,571       11,493       131,892       (590,956 )     -  
OTHER LONG-TERM LIABILITIES
    13,323       7,065       12,215       -       32,603  
                                         
Equity Component of Short-term Debt - Senior Exchangeable Notes
    -       21,871       -       -       21,871  
                                         
SHAREHOLDERS' EQUITY
    231,957       160,648       2,179,667       (2,340,315 )     231,957  
NON-CONTROLLING INTEREST
    -       -       2,436       -       2,436  
TOTAL EQUITY
    231,957       160,648       2,182,103       (2,340,315 )     234,393  
                                         
TOTAL LIABILITIES AND EQUITY
  $ 701,507     $ 480,790     $ 2,410,916     $ (2,940,552 )   $ 652,661  


12

 


Condensed Consolidating Balance Sheets
                             
                               
(In thousands)
 
December 31, 2009
 
   
Core Laboratories N.V. (Parent/ Guarantor)
   
Core Laboratories LP (Issuer)
   
Other Subsidiaries (Non- Guarantors)
   
Consolidating Adjustments
   
Consolidated Total
 
ASSETS
                             
CURRENT ASSETS:
                             
Cash and cash equivalents
  $ 73,998     $ 95,048     $ 11,999     $ -     $ 181,045  
Accounts receivable, net
    1       29,452       104,305       -       133,758  
Inventories, net
    -       2,679       29,505       -       32,184  
Prepaid expenses and other current assets
    11,809       22,209       9,532       -       43,550  
Total current assets
    85,808       149,388       155,341       -       390,537  
                                         
PROPERTY, PLANT AND EQUIPMENT, net
    -       21,988       76,796       -       98,784  
GOODWILL AND INTANGIBLES, net
    46,986       7,949       100,185       -       155,120  
INTERCOMPANY RECEIVABLES
    37,681       216,670       232,802       (487,153 )     -  
INVESTMENT IN AFFILIATES
    540,724       -       1,387,715       (1,928,118 )     321  
DEFERRED TAX ASSET
    2,951       4,644       14,359       (21,954 )     -  
OTHER ASSETS
    2,828       8,770       1,806       -       13,404  
TOTAL ASSETS
  $ 716,978     $ 409,409     $ 1,969,004     $ (2,437,225 )   $ 658,166  
                                         
LIABILITIES AND EQUITY
                                 
CURRENT LIABILITIES:
                                       
Accounts payable
  $ 501     $ 6,404     $ 26,104     $ -     $ 33,009  
Other accrued expenses
    673       29,738       42,988       -       73,399  
Total current liabilities
    1,174       36,142       69,092       -       106,408  
                                         
LONG-TERM DEBT
    -       209,112       -       -       209,112  
DEFERRED COMPENSATION
    6,046       10,094       726       -       16,866  
DEFERRED TAX LIABILITY
    -       29,646       -       (21,954 )     7,692  
INTERCOMPANY PAYABLES
    417,618       -       69,535       (487,153 )     -  
OTHER LONG-TERM LIABILITIES
    12,772       7,702       15,856       -       36,330  
                                         
SHAREHOLDERS' EQUITY
    279,368       116,713       1,811,405       (1,928,118 )     279,368  
NON-CONTROLLING INTEREST
    -       -       2,390       -       2,390  
TOTAL EQUITY
    279,368       116,713       1,813,795       (1,928,118 )     281,758  
                                         
TOTAL LIABILITIES AND EQUITY
  $ 716,978     $ 409,409     $ 1,969,004     $ (2,437,225 )   $ 658,166  









13

 


Condensed Consolidating Statements of Operations (Unaudited)
                         
                               
(In thousands)
 
Three Months Ended June, 2010
 
   
Core Laboratories N.V. (Parent/ Guarantor)
   
Core Laboratories LP (Issuer)
   
Other Subsidiaries (Non- Guarantors)
   
Consolidating Adjustments
   
Consolidated Total
 
REVENUES
                             
Operating revenues
  $ -     $ 48,386     $ 150,516     $ -     $ 198,902  
Intercompany revenues
    379       7,619       35,451       (43,449 )     -  
Earnings from consolidated affiliates
    37,709       -       115,745       (153,454 )     -  
Total revenues
    38,088       56,005       301,712       (196,903 )     198,902  
                                         
OPERATING EXPENSES
                                       
Operating costs
    322       25,237       103,358       -       128,917  
General and administrative expenses
    2,147       7,060       4       -       9,211  
Depreciation and amortization
    -       1,554       4,212       -       5,766  
Other expense (income), net
    992       3,411       29,884       (32,999 )     1,288  
                                         
Operating income
    34,627       18,743       164,254       (163,904 )     53,720  
Interest expense
    -       4,112       2       -       4,114  
                                         
Income before income tax expense
    34,627       14,631       164,252       (163,904 )     49,606  
Income tax expense (benefit)
    411       5,992       8,841       -       15,244  
                                         
Net income
    34,216       8,639       155,411       (163,904 )     34,362  
Net income attributable to non-controlling interest
    -       -       146       -       146  
                                         
Net income attributable to Core Laboratories
  $ 34,216     $ 8,639     $ 155,265     $ (163,904 )   $ 34,216  



Condensed Consolidating Statements of Operations (Unaudited)
                         
                               
(In thousands)
 
Six Months Ended June 30, 2010
 
   
Core Laboratories N.V. (Parent/ Guarantor)
   
Core Laboratories LP (Issuer)
   
Other Subsidiaries (Non- Guarantors)
   
Consolidating Adjustments
   
Consolidated Total
 
REVENUES
                             
Operating revenues
  $ -     $ 93,547     $ 293,692     $ -     $ 387,239  
Intercompany revenues
    667       12,206       70,960       (83,833 )     -  
Earnings from consolidated affiliates
    72,898       -       216,504       (289,402 )     -  
Total revenues
    73,565       105,753       581,156       (373,235 )     387,239  
                                         
OPERATING EXPENSES
                                       
Operating costs
    712       50,221       203,572       -       254,505  
General and administrative expenses
    4,314       11,270       7       -       15,591  
Depreciation and amortization
    -       3,112       8,408       -       11,520  
Other expense (income), net
    857       5,002       58,192       (63,561 )     490  
                                         
Operating income
    67,682       36,148       310,977       (309,674 )     105,133  
Interest expense
    -       8,167       6       -       8,173  
                                         
Income before income tax expense
    67,682       27,981       310,971       (309,674 )     96,960  
Income tax expense (benefit)
    1,261       11,474       17,577       -       30,312  
                                         
Net income
    66,421       16,507       293,394       (309,674 )     66,648  
Net income attributable to non-controlling interest
    -       -       227       -       227  
                                         
Net income attributable to Core Laboratories
  $ 66,421     $ 16,507     $ 293,167     $ (309,674 )   $ 66,421  


14

 


Condensed Consolidating Statements of Cash Flows (Unaudited)
                         
                               
(In thousands)
 
Six Months Ended June 30, 2010
 
   
Core Laboratories N.V. (Parent/ Guarantor)
   
Core Laboratories LP (Issuer)
   
Other Subsidiaries (Non- Guarantors)
   
Consolidating Adjustments
   
Consolidated Total
 
                               
Net cash provided by operating activities
  $ 54,349     $ 44,964     $ 12,047     $ -     $ 111,360  
                                         
CASH FLOWS FROM INVESTING ACTIVITIES:
                                 
Capital expenditures
    -       (2,918 )     (9,778 )     -       (12,696 )
Patents and other intangibles
    -       -       (142 )     -       (142 )
Acquisitions, net of cash
    -       (9,000 )     -       -       (9,000 )
Proceeds from sale of assets
    -       11       114       -       125  
Premiums on life insurance
    -       (921 )     -       -       (921 )
Net cash used in investing activities
    -       (12,828 )     (9,806 )     -       (22,634 )
                                         
CASH FLOWS FROM FINANCING ACTIVITIES:
                                 
Stock options exercised
    295       -       -       -       295  
Excess tax benefit from stock-based payments
    798       -       -       -       798  
Non-controlling interest - dividends
    -       -       (181 )     -       (181 )
Dividends paid
    (5,375 )     -       -       -       (5,375 )
Repurchase of common shares
    (91,686 )     -       -       -       (91,686 )
Net cash used in financing activities
    (95,968 )     -       (181 )     -       (96,149 )
                                         
NET CHANGE IN CASH AND CASH EQUIVALENTS
    (41,619 )     32,136       2,060       -       (7,423 )
CASH AND CASH EQUIVALENTS, beginning of period
    73,998       95,048       11,999       -       181,045  
CASH AND CASH EQUIVALENTS, end of period
  $ 32,379     $ 127,184     $ 14,059     $ -     $ 173,622  


Condensed Consolidating Statements of Operations (Unaudited)
                         
                               
(In thousands)
 
Three Months Ended June 30, 2009
 
   
Core Laboratories N.V. (Parent/ Guarantor)
   
Core Laboratories LP (Issuer)
   
Other Subsidiaries (Non- Guarantors)
   
Consolidating Adjustments
   
Consolidated Total
 
REVENUES
                             
Operating revenues
  $ -     $ 40,675     $ 126,587     $ -     $ 167,262  
Intercompany revenues
    355       6,758       19,745       (26,858 )     -  
Earnings from consolidated affiliates
    33,141       -       93,831       (126,972 )     -  
Total revenues
    33,496       47,433       240,163       (153,830 )     167,262  
                                         
OPERATING EXPENSES
                                       
Operating costs
    308       21,426       87,263       -       108,997  
General and administrative expenses
    1,992       4,689       3       -       6,684  
Depreciation and amortization
    -       1,379       4,527       -       5,906  
Other expense (income), net
    (3,282 )     3,499       24,454       (30,684 )     (6,013 )
                                         
Operating income
    34,478       16,440       123,916       (123,146 )     51,688  
Interest expense
    418       3,411       11       -       3,840  
                                         
Income before income tax expense
    34,060       13,029       123,905       (123,146 )     47,848  
Income tax expense (benefit)
    4,253       6,652       6,979       -       17,884  
                                         
Net income
    29,807       6,377       116,926       (123,146 )     29,964  
Net income attributable to non-controlling interest
    -       -       157       -       157  
                                         
Net income attributable to Core Laboratories
  $ 29,807     $ 6,377     $ 116,769     $ (123,146 )   $ 29,807  


15

 



Condensed Consolidating Statements of Operations (Unaudited)
                         
                               
(In thousands)
 
Six Months Ended June 30, 2009
 
   
Core Laboratories N.V. (Parent/ Guarantor)
   
Core Laboratories LP (Issuer)
   
Other Subsidiaries (Non- Guarantors)
   
Consolidating Adjustments
   
Consolidated Total
 
REVENUES
                             
Operating revenues
  $ -     $ 85,809     $ 260,329     $ -     $ 346,138  
Intercompany revenues
    698       13,357       49,745       (63,800 )     -  
Earnings from consolidated affiliates
    63,428       -       186,484       (249,912 )     -  
Total revenues
    64,126       99,166       496,558       (313,712 )     346,138  
                                         
OPERATING EXPENSES
                                       
Operating costs
    620       45,031       179,378       -       225,029  
General and administrative expenses
    5,452       10,499       7       -       15,958  
Depreciation and amortization
    -       2,748       8,866       -       11,614  
Other expense (income), net
    (3,293 )     7,634       52,022       (61,133 )     (4,770 )
                                         
Operating income
    61,347       33,254       256,285       (252,579 )     98,307  
Interest expense
    893       6,716       31       -       7,640  
                                         
Income before income tax expense
    60,454       26,538       256,254       (252,579 )     90,667  
Income tax expense (benefit)
    1,455       11,438       18,571       -       31,464  
                                         
Net income
    58,999       15,100       237,683       (252,579 )     59,203  
Net income attributable to non-controlling interest
    -       -       204       -       204  
                                         
Net income attributable to Core Laboratories
  $ 58,999     $ 15,100     $ 237,479     $ (252,579 )   $ 58,999  


Condensed Consolidating Statements of Cash Flows (Unaudited)
                         
                               
(In thousands)
 
Six Months Ended June 30, 2009
 
   
Core Laboratories N.V. (Parent/ Guarantor)
   
Core Laboratories LP (Issuer)
   
Other Subsidiaries (Non- Guarantors)
   
Consolidating Adjustments
   
Consolidated Total
 
                               
Net cash provided by operating activities
  $ 39,495     $ 39,163     $ 7,609     $ -     $ 86,267  
                                         
CASH FLOWS FROM INVESTING ACTIVITIES:
                                 
Capital expenditures
    -       (1,022 )     (4,298 )     -       (5,320 )
Patents and other intangibles
    -       -       (151 )     -       (151 )
Proceeds from sale of assets
    -       175       284       -       459  
Premiums on life insurance
    -       (844 )     -       -       (844 )
Net cash used in investing activities
    -       (1,691 )     (4,165 )     -       (5,856 )
                                         
CASH FLOWS FROM FINANCING ACTIVITIES:
                                 
Stock options exercised
    302       -       -       -       302  
Excess tax benefit from stock-based payments
    127       -       -       -       127  
Non-controlling interest - dividends
    -       -       (246 )     -       (246 )
Dividends paid
    (4,597 )     -       -       -       (4,597 )
Repurchase of common shares
    (8,889 )     -       -       -       (8,889 )
Net cash used in financing activities
    (13,057 )     -       (246 )     -       (13,303 )
                                         
NET CHANGE IN CASH AND CASH
   EQUIVALENTS
    26,438       37,472       3,198       -       67,108  
CASH AND CASH EQUIVALENTS,
   beginning of period
    13,347       11,027       11,764       -       36,138  
CASH AND CASH EQUIVALENTS,
   end of period
  $ 39,785     $ 48,499     $ 14,962     $ -     $ 103,246  


16

 


Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion summarizes the financial position of Core Laboratories N.V. and its subsidiaries as of June 30, 2010 and should be read in conjunction with (i) the unaudited consolidated interim financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q and (ii) the consolidated financial statements and accompanying notes to our Annual Report on Form 10-K for the fiscal year ended December 31, 2009.

General

Core Laboratories N.V. is a Netherlands limited liability company.  It was established in 1936 and is one of the world's leading providers of proprietary and patented reservoir description, production enhancement and reservoir management products and services to the oil and gas industry.  These products and services can enable our clients to improve reservoir performance and increase oil and gas recovery from their producing fields.  Core Laboratories N.V. has over 70 offices in more than 50 countries and employs approximately 5,000 people worldwide.

References to "Core Lab", "we", "our" and similar phrases are used throughout this Quarterly Report on Form 10-Q and relate collectively to Core Laboratories N.V. and its consolidated affiliates.

Our business units have been aggregated into three complementary segments, which provide products and services for improving reservoir performance and increasing oil and gas recovery from new and existing fields.

*
Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.
   
*
Production Enhancement: Includes products and services relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
   
*
Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Certain statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations section, including those under the headings "Outlook" and "Liquidity and Capital Resources", and in other parts of this Form 10-Q, are forward-looking. In addition, from time to time, we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. Forward-looking statements can be identified by the use of forward-looking terminology such as "may", "will", "believe", "expect", "anticipate", "estimate", "continue", or other similar words, including statements as to the intent, belief, or current expectations of our directors, officers, and management with respect to our future operations, performance, or positions or which contain other forward-looking information. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. While management believes that these forward-looking statements are reasonable as and when made, no assurances can be given that the future results indicated, whether expressed or implied, will be achieved. Our actual results may differ significantly from the results discussed in the forward-looking statements. While we believe that these statements are and will be accurate, a variety of factors could cause our actual results and experience to differ materially from the anticipated results or other expectations expressed in our statements. Such factors include, but are not limited to, the risks and uncertainties summarized below:

-
general and economic business conditions;
   
-
market prices of oil and gas and expectations about future prices;
   
-
cost of producing oil and natural gas;
   
-
the level of drilling and production activity;
   
-
mergers, consolidations and downsizing among our clients;
   
-
coordination by OPEC;

17

 


   
-
the impact of commodity prices on the expenditure levels of our clients;
   
-
financial condition of our client base and their ability to fund capital expenditures;
   
-
the physical and/or financial effects of climatic change, including adverse weather or geologic/geophysical conditions;
   
-
the adoption of legal requirements or taxation relating to climate change that lower the demand for petroleum-based fuels;
   
-
civil unrest in oil producing or consuming countries;
   
-
level of consumption of oil, gas and petrochemicals by consumers;
   
-
changes in existing laws, regulations, or other governmental actions;
   
-
the business opportunities (or lack thereof) that may be presented to and pursued by us; and
   
-
availability of services and materials for our clients to grow their capital expenditures.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in the forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed discussion of some of the foregoing risks and uncertainties, see "Item 1A - Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as well as the other reports filed by us with the Securities and Exchange Commission (“SEC”).

Outlook

We continue our efforts to expand our market presence by opening facilities in strategic areas and realizing synergies within our business lines.  We believe our market presence provides us a unique opportunity to service customers who have global operations in addition to the national oil companies.

We have established internal earnings targets that are based on market conditions existing at the time our targets were established.  Based on recent developments, we believe that the current level of activities, workflows, and operating margins outside North America will grow at moderate rates and that North American onshore activity will also grow at moderate rates.  Deepwater activity in the Gulf of Mexico is currently suspended by US governmental decree.

18

 


Results of Operations

Our results of operations as a percentage of applicable revenue were as follows (in thousands):

(Unaudited)
 
Three Months Ended June 30,
   
% Change
 
   
2010
   
2009
      2010/2009  
REVENUES:
             
Services
  $ 153,010       77   $ 134,671       81     14
Product sales
    45,892       23     32,591       19     41
  Total revenues
    198,902       100     167,262       100     19
OPERATING EXPENSES:
                                       
Cost of services*
    96,411       63     84,401       63     14
Cost of product sales*
    32,506       71     24,596       75     32
  Total cost of services and product sales
    128,917       65     108,997       65     18
General and administrative expenses
    9,211       4     6,684       4     38
Depreciation and amortization
    5,766       3     5,906       4     (2 %)
Other expense (income), net
    1,288       1     (6,013 )     (4 %)     (121 %)
Operating income
    53,720       27     51,688       31     4
Interest expense
    4,114       2     3,840       2     7
Income before income tax expense
    49,606       25     47,848       29     4
Income tax expense
    15,244       8     17,884       11     (15 %)
Net income
    34,362       17     29,964       18     15
Net income attributable to non-controlling interest
    146       -       157       -       (7 %)
Net income attributable to Core Laboratories N.V.
  $ 34,216       17   $ 29,807       18     15
                                         
*Percentage based on applicable revenue rather than total revenue
                 


(Unaudited)
 
Six Months Ended June 30,
   
% Change
 
   
2010
   
2009
      2010/2009  
REVENUES:
             
Services
  $ 296,452       77   $ 276,363       80     7
Product sales
    90,787       23     69,775       20     30
  Total revenues
    387,239       100     346,138       100     12
OPERATING EXPENSES:
                                       
Cost of services*
    191,768       65     172,697       62     11
Cost of sales*
    62,737       69     52,332       75     20
  Total cost of services and sales
    254,505       66     225,029       65     13
General and administrative expenses
    15,591       4     15,958       5     (2 %)
Depreciation and amortization
    11,520       3     11,614       3     (1 %)
Other expense, net
    490       -       (4,770 )     (1 %)     (110 %)
Operating income
    105,133       27     98,307       28     7
Interest expense
    8,173       2     7,640       2     7
Income before income tax expense
    96,960       25     90,667       26     7
Income tax expense
    30,312       8     31,464       9     (4 %)
Net income
    66,648       17     59,203       17     13
Net income attributable to non-controlling interest
    227       -       204       -       11
Net income attributable to Core Laboratories N.V.
  $ 66,421       17   $ 58,999       17     13
                                         
*Percentage based on applicable revenue rather than total revenue
                 



19

 


Operating Results for the Three and Six Months Ended June 30, 2010 Compared to the Three and Six Months Ended June 30, 2009 (unaudited)

Service Revenues

Service revenues increased to $153.0 million for the second quarter of 2010, up 14% when compared to $134.7 million for the second quarter of 2009. For the six months ended June 30, 2010, service revenues increased 7% to $296.5 million compared to $276.4 million for the respective period in 2009.  The increase in service revenues was due, in part, to the increased demand for reservoir fluids phase-behavior studies, and for crude oil testing, inspection, distillation, assay, fractionation and characterization projects worldwide.  Our large scale core analyses and advance rock properties studies from the eastern Mediterranean region, the Middle East, and both South Atlantic offshore margins also provided meaningful revenue streams.  Activity in North American Gas Shale plays has accelerated in the first half of 2010 leading to growth in stimulation related projects.

Product Sales Revenues

Revenues associated with product sales increased to $45.9 million for the second quarter of 2010, up 41% from $32.6 million for the second quarter of 2009. For the six months ended June 30, 2010, product sale revenues increased 30% to $90.8 million compared to $69.8 million for the same period in 2009. The increase in revenue was driven by the acceptance and demand of our specialized completion products introduced over the last three years and has led to increased market share in North American natural gas and oil shale reservoirs and has increased market penetration in Middle East and Asia-Pacific perforating markets.  These specialized optimizing technologies are focused on high-end well completion and stimulation programs mainly in the Haynesville, Marcellus, Montney and Eagle Ford shale plays and in multi-stage completions in the Bakken oil-shale play. We are also providing high margin completion and recompletion technologies and services to be used in reworking major, giant, and super giant fields in southern Iraq.

Cost of Services

Cost of services expressed as a percentage of service revenue was 63% for the quarter ended June 30, 2010, which was unchanged from the same period in 2009.  For the six months ended June 30, 2010, cost of services expressed as a percentage of service revenue was 65% as compared to 62% for the same period in 2009.  The increase in the cost of services relative to service revenue was primarily a result of slightly higher sales of lower margins services.

Cost of Product Sales

Cost of sales as a percentage of product sales revenues was 71% for the quarter ended June 30, 2010, down from 75% for the same period in 2009. For the six months ended June 30, 2010, cost of product sales expressed as a percentage of sales revenue was 69%, down from 75% for the same period in 2009. The decrease in cost of sales as a percentage of product sale revenues was primarily due to the growing demand for our new technologies which are our higher margin products and from an overall increase in sales which improved absorption of our fixed cost structure and increased manufacturing efficiencies with the increased volume of product sales.
 
 
General and Administrative Expenses

General and administrative expenses totaled $9.2 million for the second quarter of 2010, up 38% from the $6.7 million incurred in the second quarter of 2009 due to compensation related expenses and additional facilities maintenance expenses. For the six months ended June 30, 2010 and 2009, general and administrative expenses were comparable at $15.6 million and $16.0 million, respectively.

Depreciation and Amortization Expense

Depreciation and amortization expense decreased to $5.8 million for the second quarter of 2010, down 2% when compared to $5.9 million for the second quarter of 2009.  For the six months ended June 30, 2010, depreciation and amortization expense was $11.5 million, a decrease of $0.1 million from the six months ended June 30, 2009.

20

 


Other Expense (Income), Net

Other expense (income), net consisted of the following for the quarter ended June 30, 2010 and 2009 (in thousands):

   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2010
   
2009
   
2010
   
2009
 
   
(Unaudited)
   
(Unaudited)
 
Gain on sale of assets
  $ 39     $ (268 )   $ 8     $ (345 )
Foreign exchange loss (gain)
    1,712       (2,897 )     1,621       (1,009 )
Interest income
    (130 )     (59 )     (142 )     (98 )
Non-income tax accrual
    -       (2,500 )     -       (2,500 )
Rents and royalties
    (218 )     (508 )     (700 )     (849 )
Other, net
    (115 )     219       (297 )     31  
  Total other expense (income), net
  $ 1,288     $ (6,013 )   $ 490     $ (4,770 )

As a result of finalizing a non-income related tax settlement agreement, we released the remaining $2.5 million of the contingent liability during the second quarter of 2009.

Foreign exchange losses (gains) by currency are summarized in the following table (in thousands):

   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2010
   
2009
   
2010
   
2009
 
   
(Unaudited)
   
(Unaudited)
 
Australian Dollar
  $ 103     $ (300 )   $ 103     $ (278 )
British Pound
    158       (304 )     416       (232 )
Canadian Dollar
    149       (1,115 )     (236 )     (767 )
Euro
    1,619       (376 )     1,589       (213 )
Russian Ruble
    (69 )     (372 )     (15 )     224  
Venezuelan Bolivar
    (202 )     (1 )     (191 )     (1 )
Other currencies, net
    (46 )     (429 )     (45 )     258  
  Total loss (gain)
  $ 1,712     $ (2,897 )   $ 1,621     $ (1,009 )

Income Tax Expense

The effective tax rates for the three months ended June 30, 2010 and 2009 were 30.7% and 37.4%, respectively.  The higher effective tax rate for 2009 was due primarily to a write down of assets in Venezuela without a tax benefit in the second quarter of last year.

Segment Analysis

Our operations are managed primarily in three complementary segments - Reservoir Description, Production Enhancement and Reservoir Management.  The following tables summarize our results by operating segment for the three months ended June 30, 2010 and 2009 (in thousands):

21

 


   
Three Months Ended
June 30,
   
% Change
 
   
2010
   
2009
      2010/2009  
Revenues:
 
(Unaudited)
         
Reservoir Description
  $ 106,528     $ 103,479       3
Production Enhancement
    79,717       52,014       53
Reservoir Management
    12,657       11,769       8
   Consolidated
  $ 198,902     $ 167,262       19
                         
Operating income:
                       
Reservoir Description
  $ 25,074     $ 31,462       (20 %)
Production Enhancement
    26,152       14,419       81
Reservoir Management
    3,672       3,484       5
Corporate and Other1
    (1,178 )     2,323    
NM
 
   Consolidated
  $ 53,720     $ 51,688       4
                         
(1) "Corporate and Other" represents those items that are not directly related to a particular segment
 
"NM"  means not meaningful
 

   
Six Months Ended
June 30,
   
% Change
 
   
2010
   
2009
      2010/2009  
Revenues:
 
(Unaudited)
         
Reservoir Description
  $ 210,621     $ 206,002       2
Production Enhancement
    148,561       115,114       29
Reservoir Management
    28,057       25,022       12
   Consolidated
  $ 387,239     $ 346,138       12
                         
Operating income:
                       
Reservoir Description
  $ 50,215     $ 56,214       (11 %)
Production Enhancement
    47,095       32,743       44
Reservoir Management
    9,292       6,962       33
Corporate and Other1
    (1,469 )     2,388    
NM
 
   Consolidated
  $ 105,133     $ 98,307       7
                         
(1) "Corporate and Other" represents those items that are not directly related to a particular segment
 
"NM"  means not meaningful
 

Reservoir Description

Revenues from the Reservoir Description segment increased 3%, or $3.0 million, to $106.5 million in the second quarter of 2010, compared to $103.5 million in the second quarter of 2009.  For the six months ended June 30, 2010, revenues increased 2%, or $4.6 million, to $210.6 million from $206.0 million for the six months ended June 30, 2009. This segment’s operations continued to benefit from large-scale core analyses and advanced rock properties studies from the eastern Mediterranean region, the Middle East and both South Atlantic offshore margins.  This segment continued to realize increased demand for reservoir fluids phase-behavior studies, and for crude oil testing, inspection, distillation, assay, fractionation and characterization projects worldwide.

Operating income in the second quarter of 2010 decreased by 20%, or $6.4 million, to $25.1 million compared to $31.5 million for the second quarter of 2009.  Operating income for the six months ended June 30, 2010 decreased by 11%, or $6.0 million, to $50.2 million.  Operating margins for the quarter and six months ended June 30, 2010 were 24% for both periods, compared to 30% and 27% for the same periods in 2009, respectively. This segment continues to focus on emphasizing higher value, and thus higher margin, services on internationally-based development and production-related crude oil projects in addition to de-emphasizing the more cyclical exploration-related projects.  As a result of the industry slow-down experienced in 2009, we delayed implementing certain compensation programs in an effort to reduce our cost structure. Those programs were instituted in the first half of 2010 which increased our cost structure without the benefit of a corresponding increase in revenue. 

22

 


Production Enhancement

Revenues from the Production Enhancement segment increased by 53%, or $27.7 million, to $79.7 million in the second quarter of 2010 as compared to $52.0 million in the second quarter of 2009. Revenues increased by 29%, or $33.5 million, to $148.6 million for the six months ended June 30, 2010 as compared to $115.1 million for the same period in 2009.  The revenue increase was due to the increased acceptance by our clients of our high margin completion products as well as our fracture diagnostic services, and an increased market share of our perforating charges and gun systems particularly in the North American natural gas market.

Operating income in the second quarter of 2010 increased by 81%, or $11.8 million, to $26.2 million from $14.4 million for the second quarter of 2009.  Operating margins increased to 33% in the second quarter of 2010 compared to 28% for the same period in 2009.  For the six months ended June 30, 2010, operating income increased to $47.1 million, an increase of 44% over the same period in 2009.  The increase in margins was primarily driven by our continued market penetration of higher-margin services including our proprietary and patented diagnostic technologies, such as SpectraChem® Plus+, SpectraScan®, ZeroWash®, and our HERO™ line of perforating charges and gun systems.  This segment also began providing high margin completion and recompletion technologies and services to be used in the reworking of major, giant, and super giant fields in southern Iraq.

Reservoir Management

Revenues from the Reservoir Management segment increased by 8% in the second quarter of 2010 compared to the second quarter of 2009.  Revenues for the six months ended June 30, 2010 were $28.1 million, an increase of 12% from $25.0 million from the same period in 2009. The increase in revenue was due to ongoing interest in several of our existing multi-client reservoir studies including studies in the Montney Shale in northeastern British Columbia and northern Alberta, and the Eagle Ford Shale in south Texas, along with the continued participation in our North American Gas Shale Study.  In addition, increased revenue was provided by our proprietary studies which parallel our joint-industry projects, including studies of offshore Ivory Coast and Nigeria and a gas-shale reconnaissance project in Indonesia.

Operating income in the second quarter of 2010 increased 5% to $3.7 million from $3.5 million for the second quarter of 2009. For the six months ended June 30, 2010, operating income was $9.3 million, compared to operating income of $7.0 million from the same period in 2009. The increase in operating income was primarily related to growth in our consortium projects and the timing of our analysis work on these projects.

Liquidity and Capital Resources

General

We have historically financed our activities through cash on hand, cash flows from operations, bank credit facilities, or the issuance of debt and equity financing.

We utilize the non-GAAP financial measure of free cash flow to evaluate our cash flows and results of operations.  Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less capital expenditures.  Management believes that free cash flow provides useful information to investors regarding the cash that was available in the period that was in excess of our needs to fund our capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP, and should not be considered in isolation nor construed as an alternative to operating profit, net income (loss) or cash flows from operating, investing or financing activities, each as determined in accordance with GAAP. Free cash flow does not represent residual cash available for distribution because we may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented, may not be comparable to similarly titled measures presented by other companies.  The following table reconciles this non-GAAP financial measure to the most directly comparable measure calculated and presented in accordance with GAAP for the six months ended June 30, 2010 and 2009 (in thousands):

23

 


   
Six Months Ended
June 30,
   
% Change
 
   
2010
   
2009
      2010/2009  
Free cash flow calculation:
 
(Unaudited)
         
Net cash provided by operating activities
  $ 111,360     $ 86,267       29
Less:  capital expenditures
    12,696       5,320       139
    Free cash flow
  $ 98,664     $ 80,947       22

The increase in free cash flow in 2010 compared to 2009 was due to an increase in net income and improved working capital excluding cash and senior exchangeable notes, primarily from the utilization of income tax receivables.

Cash Flows

The following table summarizes cash flows for the six months ended June 30, 2010 and 2009 (in thousands):

   
Six Months Ended
June 30,
   
% Change
 
   
2010
   
2009
      2010/2009  
Cash provided by/(used in):
 
(Unaudited)
         
    Operating activities
  $ 111,360     $ 86,267       29
    Investing activities
    (22,634 )     (5,856 )     287
    Financing activities
    (96,149 )     (13,303 )     623
Net change in cash and cash equivalents
  $  (7,423 )   $ 67,108       (111 %)

The increase in cash flows provided by operating activities was primarily attributable to an increase in net income and improved working capital excluding cash and senior exchangeable notes, due to the realization of income tax receivables.

Cash flows used in investing activities increased due to higher capital expenditures of $12.7 million for the period and an acquisition for $9.0 million.

The increase in cash flows used in financing activities relates primarily to an increase in the number of shares repurchased under our common share repurchase program.  In the first six months of 2010, we repurchased 1,483,280 shares for an aggregate price of $91.7 million compared to 268,648 shares for an aggregate price of $8.9 million during the same period in 2009.

In 2006, Core Laboratories LP, a wholly owned subsidiary of Core Laboratories N.V., issued $300 million aggregate principal amount of Senior Exchangeable Notes (the "Notes") which are fully and unconditionally guaranteed by Core Laboratories N.V. and mature on October 31, 2011.

Under the terms of the Notes, on June 30, 2010, the early exchange option for the holders of the Notes was enabled. As a result, the Notes can be exchanged during the third quarter of 2010 and will remain classified as a short-term liability.  On March 31, 2010, the early exchange option was enabled allowing the holders of the Notes to exchange them during the second quarter of 2010.  We received six requests during the second quarter of 2010 to exchange 28 Notes.

We maintain a revolving credit facility (the "Credit Facility") that allows for an aggregate borrowing capacity of $100.0 million. The Credit Facility provides an option to increase the commitment under the Credit Facility to $150.0 million, if certain conditions are met.  The Credit Facility bears interest at variable rates from LIBOR plus 0.5% to a maximum of LIBOR plus 1.125%.  Any outstanding balance under the Credit Facility is due in December 2010 when the Credit Facility matures.  Interest payment terms are variable depending upon the specific type of borrowing under this facility. Our available borrowing capacity under the Credit Facility is reduced by outstanding letters of credit and performance guarantees and bonds arranged under the Credit Facility which totaled $12.6 million at June 30, 2010 and related to certain projects in progress.  Our available borrowing capacity under the Credit Facility at June 30, 2010 was $87.4 million. As of June 30, 2010, we had $14.9 million of outstanding letters of credit and performance guarantees and bonds in addition to those under the Credit Facility.

The terms of the Credit Facility require us to meet certain financial and operational covenants. We believe that we were in compliance with all such covenants at June 30, 2010.  All of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility.

24

 


Our ability to maintain and grow our operating income and cash flow depends, to a large extent, on continued investing activities. We are a Netherlands holding company and substantially all of our operations are conducted through subsidiaries. Consequently, our cash flow depends upon the ability of our subsidiaries to pay cash dividends or otherwise distribute or advance funds to us.  We believe our future cash flows from operations, supplemented by our borrowing capacity and issuances of additional equity should be sufficient to fund our debt requirements, capital expenditures, working capital, dividend payments and future acquisitions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in market risk from the information provided in Item 7A. "Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009.

Item 4. Controls and Procedures

A complete discussion of our controls and procedures is included in our Annual Report on Form 10-K for the year ended December 31, 2009.

Disclosure Controls and Procedures
Our management, under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of the end of the period covered by this report.  Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure and is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.  Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2010 at the reasonable assurance level.

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.  Further, the design of disclosure controls and internal control over financial reporting must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting
 
There have been no changes in our system of internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our fiscal quarter ended June 30, 2010, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 

25

 

CORE LABORATORIES N.V.
 
PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

See Note 6 of Consolidated Interim Financial Statements in Part I, Item 1.


Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information about purchases of equity securities that are registered by us pursuant to Section 12 of the Exchange Act during the quarter ended June 30, 2010:

Period
 
Total Number of Shares Purchased
   
Average Price Paid Per Share
   
Total Number of Shares Purchased as Part of a Publicly Announced Program
   
Maximum Number of Shares That May Yet be Purchased Under the Program (4)
 
April 1-30, 2010 (1)
    11,232     $ 66.56       11,232       6,678,359  
May 1-31, 2010 (2)
    53,178       68.74       53,178       6,671,481  
June 1-30, 2010 (3)
    11,066       73.78       11,066       6,702,213  
Total
    75,476     $ 69.15       75,476          

(1) Contains 11,232 shares valued at approximately $0.7 million, or $66.56 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award in April 2010.
(2) Contains 13,178 shares valued at approximately $0.9 million, or $70.27 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award in May 2010.
(3) Contains 11,066 shares valued at approximately $0.8 million, or $73.78 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award in June 2010.
(4) In connection with our initial public offering in September 1995, our shareholders authorized our Management Board to repurchase up to 10% of our issued share capital, the maximum allowed under Dutch law at the time, for a period of 18 months.  This authorization was renewed at subsequent annual or special shareholder meetings.  At our annual shareholders’ meeting on June 10, 2010, following a change in Dutch law that permitted us to repurchase up to 50% of our issued share capital in open market purchases, subject to shareholder approval, our shareholders authorized an extension through December 10, 2011 to purchase up to 25.6% of our issued share capital, consisting of 10% of our issued shares and an additional 15.6% of our issued shares to fulfill obligations relating to the Notes or warrants. The repurchase of shares in the open market is at the discretion of management pursuant to this shareholder authorization.




26

 




Exhibit No.
 
Incorporated by reference from the following documents
3.1
-
Articles of Association of Core Laboratories N.V., as amended (including English translation)
Filed herewith
31.1
-
Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Filed herewith
31.2
-
Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Filed herewith
32.1
-
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Furnished herewith
32.2
-
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Furnished herewith
       


27

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, Core Laboratories N.V., has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 
CORE LABORATORIES N.V.
 
By:
Core Laboratories International B.V., its
   
Managing Director
     
Date:
July 23, 2010
By:
/s/ Richard L. Bergmark
   
Richard L. Bergmark
   
Chief Financial Officer
   
(Duly Authorized Officer and
   
Principal Financial Officer)

 

 


28